Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
Launched by STANFORD UNIVERSITY ·
Trial Information
Current as of September 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well children and young people with anxiety or mood disorders engage with therapy when it’s delivered through a special virtual platform called Teleo, compared to regular video calls. The goal is to see if Teleo, which is designed especially for youth psychotherapy, helps keep patients involved and engaged during their treatment.
The study is open to all genders, but it’s important to note that participants need to be between the ages of 18 to 26 or 51 to 113—this unusual age range might be a typo or specific to the study design. If you or your family member fits this age group and is receiving therapy for anxiety or mood issues, you might be eligible. Participants will take part in therapy sessions through either the Teleo platform or standard video calls, and researchers will observe how engaged they are during these sessions. The study is not yet recruiting, so if you’re interested, keep an eye out for updates.
Gender
ALL
Eligibility criteria
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
David S Hong, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported